For the Inventor, By the Inventor

Enter assignee name

Redwood City, CA, United States of America

Biomea Fusion, Inc.

USPTO Granted Patents = 11

Trademarks = 4

Forward Citations = 22

Loading Chart...

Loading Chart...

36 inventors (with patents filed for the assignee):

Thomas Butler (10 out of 23 patents)

Jim Palmer (7 out of 7 patents)

Ravi Upasani (7 out of 10 patents)

4. Matthew Welsch (7 out of 12 patents)

5. Edward Painter (7 out of 7 patents)

6. Sridhar Vempati (7 out of 8 patents)

7. Brendan Kelly (7 out of 7 patents)

8. James T Palmer (4 out of 5 patents)

9. Nan-Horng Lin (2 out of 42 patents)

10. Thorsten A Kirschberg (2 out of 42 patents)

11. Angelina Sau Man Wong (2 out of 2 patents)

12. Heow Meng Tan (2 out of 2 patents)

13. Hongyan He (2 out of 2 patents)

14. Yongli Su (1 out of 7 patents)

15. Ming Gao (1 out of 17 patents)

11 patents: Sort by Forward Citations

1. 12275739 - Inhibitors of menin-MLL interaction (2025-04-14),

2. 12251385 - Covalent inhibitors of menin-MLL interaction for diabetes mellitus (2025-03-18),

3. 12215113 - Crystalline forms of N[4[4-(4-Morpholinyl)-7H-Pyrrolo[2-3-D]Pyrimidin-6-yl]Phenyl]-4-[[3(R)-[(1-Oxo-2-Protein-1-yl)Amino]-1-Piperidinyl]Methyl]2-Pyridinecarboxamide] (2025-02-04),

4. 12116371 - Substituted pyridines as irreversible inhibitors of menin-MLL interaction (2024-10-15),

5. 12077544 - Irreversible inhibitors of menin-MLL interaction (2024-09-03),

6. 12018032 - Crystalline forms of N-[4-[4-(4-morpholinyl)-7H-pyrrolo[2,3-d]pyrimidin-6-yl]phenyl]-4-[[3(r)-[(1-oxo-2-propen-1-yl)amino]-1-piperidinyl]methyl]-2-pyridinecarboxamide as an irreversible inhibitor of menin-MLL interaction (2024-06-25),

7. 11945785 - Pyrazine compounds as inhibitors of FLT3 (2024-04-02),

8. 11845753 - Inhibitors of menin-mll interaction (2023-12-19),

9. 11702421 - Substituted pyridines as irreversible inhibitors of menin-MLL interaction (2023-07-18),

10. 11174263 - Inhibitors of menin-MLL interaction (2021-11-16),

11. 11084825 - Substituted pyridines as irreversible inhibitors of menin-MLL interaction (2021-08-10),

Biomea Fusion, Inc. is a biotechnology company focused on developing novel therapeutics for the treatment of cancer. Our innovative approach combines cutting-edge technologies, including artificial intelligence and precision medicine, to discover and develop targeted therapies that have the potential to significantly improve patient outcomes. With a team of experienced scientists and industry experts, we are dedicated to advancing the field of oncology and bringing breakthrough treatments to patients in need.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 23 2025

11 Patents

#135 in Redwood City, CA

#6,336 in California

#26,696 in US

#50,205 in the World

Redwood City, CA, United States of America

Biomea Fusion, Inc.

Forward Citations = 22

36 inventors:

Thomas Butler (10 out of 23 patents)

Jim Palmer (7 out of 7 patents)

Ravi Upasani (7 out of 10 patents)

4. Matthew Welsch (7 out of 12 patents)

5. Edward Painter (7 out of 7 patents)

Please report any incorrect information to support@idiyas.com

Loading…